hotspot -WSS

hotspot

author：entertainment 2025-09-28 00:47:26 - browse：4

Adam's take main illustration — Molly Ferguson/STAT

Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of people with Alzheimer’s. On Friday, we learned how: The company recruited a large number of people into its clinical trial who don’t have Alzheimer’s.

People who almost certainly had Alzheimer’s were also included in the study, but in this group, a placebo outperformed Cassava’s drug.

The conclusion, of course, is obvious: Simufilam is inactive. It’s an inert compound no more effective than a placebo. Cassava’s assertion that simufilam is showing “disease-modifying activity” falls apart given its study was opened to people who should have been ineligible because they were misdiagnosed with Alzheimer’s. Whether that was done intentionally or unwittingly isn’t known, but it’s certainly troubling and makes the case for immediate, regulatory intervention even stronger.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Harvard's David Sinclair gets blowback over aging

focus

WSS

Congress needs to close a vaccine

Medicare Advantage's lean provider networks lead CMS complaints

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

STAT wants to know your pick for a great summer read or listen

Florida health officials providing scant details on measles cases

focus

hotspot

hotspot

Bright Health sells Medicare Advantage business to Molina

Biden's 'march

What does generative AI mean for health care? We asked experts

The most pressing bird flu mysteries scientists want answered

Heart attack and stroke risk calculators need revising

Senators tussle over abortion against the backdrop of a presidential campaign

Anesthesiologist group: stop taking Ozempic before surgery

CMS got Medicare Advantage quality rating wrong, judge rules

Apple is now the first public company to be valued at $3 trillion

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

leisure time

Structure Therapeutics oral GLP

Why Talkspace is targeting Medicare, a tricky market

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

STAT wants to know your pick for a great summer read or listen

He's 19 months old and has one of the world’s rarest diseases

STAT wants to know your pick for a great summer read or listen

focus

entertainment

focus

Wikipedia